MULTIPLE MYELOMA REFRACTORY

This early-phase study tests a new form of curcumin (the active ingredient in turmeric) that is wrapped in tiny fat particles to help the body absorb it better. The goal is to find the safest dose for people with multiple myeloma that has come back or stopped responding to standa…

This early-stage trial tests whether adding a drug called NT-I7 (a lab-made immune booster) can help CAR-T cells survive longer in people with multiple myeloma that has come back or stopped responding to treatment. About 52 participants who are already getting standard CAR-T ther…

This study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with relapsed or refractory multiple myeloma achieve deeper remissions. About 27 adults who have already tried at least 4 prior treatments will take selinexor alongside thei…

This study tests a new drug, inobrodib, combined with two standard medicines (pomalidomide and dexamethasone) in 100 adults whose multiple myeloma has come back or no longer responds to available therapies. The goal is to see how well the combination shrinks tumors and to learn m…

This study tests a treatment called anti BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and kill myeloma cells. The trial aims to see if it is s…

This study tests a drug called selinexor combined with a low-dose steroid (dexamethasone) in people with multiple myeloma that has stopped responding to many other treatments. Some participants will also receive another drug, bortezomib. The goal is to see if these combinations c…

This study looks at whether giving extra antibodies (immunoglobulins) can help prevent serious infections in people with multiple myeloma who are being treated with a new kind of immunotherapy called a BCMA-directed T cell engager. About 80 adults who have already tried at least …

This early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to see if t…

This study looks at whether adding early palliative care to standard treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will be randomly assigned to receive either usual care alone or usual care plus ear…